Program

The Best of ASCO Program presents the scientific and educational highlights of the ASCO Annual Meeting selected from the year’s notable abstracts. Please see the agenda for more information.

Meeting Chair: David C. Smith, MD, University of Michigan

7:00 AM–2:30 PM Exhibits Open

7:00 AM–8:00 AM

Complimentary Continental Breakfast

8:00 AM – 8:40 AM

Genitourinary (Prostate) Cancer

Alan Bryce, MD
Mayo Clinic, Phoenix

Abstract LBA3: LATITUDE: A phase III, double-blind, randomized trial of androgen deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Karim Fizazi)
Abstract 5002: A randomized phase II cross-over study of abiraterone + prednisone (ABI) vs enzalutamide (ENZ) for patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC). (Kim Chi)
Abstract LBA5003: Adding abiraterone for men with high-risk prostate cancer (PCa) starting long-term androgen deprivation therapy (ADT): Survival results from STAMPEDE (NCT00268476). (Nicholas James)
Abstract 5004: A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). (Gerhardt Attard)
Abstract 5009: Need for re-evaluation of current guidelines based on results from germline genetic testing in prostate cancer. (Piper Nicolosi)

8:40 AM–9:20 AM

Genitourinary (Nonprostate) Cancer

Daniel Geynisman, MD
Fox Chase Cancer Center

Abstract 4501: Planned survival analysis from KEYNOTE-045: Phase 3, open-label study of pembrolizumab (pembro) versus paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC). (Dean Bajorin)
Abstract 4502: Biomarker findings and mature clinical results from KEYNOTE-052: First-line pembrolizumab (pembro) in cisplatin-ineligible advanced urothelial cancer (UC). (Peter O'Donnell)
Abstract 4507: Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). (Robert Motzer)
Abstract 4508: Phase III trial of adjuvant sunitinib in patients with high-risk renal cell carcinoma (RCC): Validation of the 16-gene Recurrence Score in stage III patients. (Bernard Escudier)

9:20 AM–9:40 AM

Panel Question and Answer: Genitourinary Cancers

Alan Bryce, MD
Mayo Clinic, Phoenix

Daniel Geynisman, MD
Fox Chase Cancer Center

9:40 AM–10:00 AM

Break

10:00 AM–10:40 AM

Melanoma/Skin Cancers

Kevin Kim, MD
California Pacific Medical Center Research Institute

Abstract 9504: Long-term outcomes in patients (pts) with ipilimumab (ipi)-naive advanced melanoma in the phase 3 KEYNOTE-006 study who completed pembrolizumab (pembro) treatment. (Caroline Robert)
Abstract 9505: Five-year overall survival (OS) update from a phase II, open-label trial of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600–mutant unresectable or metastatic melanoma (MM). (Georgina Long)
Abstract 9507: Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204. (Hussein Tawbi)
Abstract 9508: A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): The Anti-PD1 Brain Collaboration (ABC). (Georgina Long)

10:40 AM–11:20 AM

Developmental Therapeutics

Ramesh K. Ramanathan, MD
Mayo Clinic, Phoenix

Abstract LBA2501: The efficacy of larotrectinib (LOXO-101), a selective tropomyosin receptor kinase (TRK) inhibitor, in adult and pediatric TRK fusion cancers. (David Hyman)
Abstract 2505: Phase I trial of a novel stapled peptide ALRN-6924 disrupting MDMX- and MDM2-mediated inhibition of WT p53 in patients with solid tumors and lymphomas. (Funda Meric-Bernstam)
Abstract 2508: First-in-class oral ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with advanced solid tumors: Final results of a phase I dose escalation and expansion study. (Bob Li)
Abstract LBA3001: Durable remissions with BCMA specific chimeric antigen receptor (CAR)-modified T cells in patients with refractory/relapsed multiple myeloma. (Frank (Xiaohu) Fan)

11:20 AM–11:40 AM

Panel Question and Answer: Melanoma/Skin Cancers & Developmental Therapeutics

Kevin Kim, MD
California Pacific Medical Center Research Institute

Ramesh K. Ramanathan, MD
Mayo Clinic, Phoenix

11:40 AM–12:30 PM

Complimentary Boxed Lunch

12:30 PM–1:10 PM

Gynecologic Cancer

Deborah K. Armstrong, MD
Sidney Kimmel Comprehensive Cancer Center

Abstract 5502: Final results of the international randomized PORTEC-3 trial of adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer. (Stephanie De Boer)
Abstract 5505: A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. (Daniela Matei)
Abstract 5506: Overall survival results of ICON6: A trial of chemotherapy and cediranib in relapsed ovarian cancer. (Jonathan Ledermann)
Abstract 5507: Health-related quality of life (HRQOL) and patient-centered outcomes with maintenance olaparib compared with placebo following chemotherapy in patients with germline (g) BRCA-mutated (m) platinum-sensitive relapsed serous ovarian cancer (PSR SOC): SOLO2 phase III trial. (Michael Friedlander)

1:10 PM–1:20 PM

Question and Answer: Gynecologic Cancer

Deborah K. Armstrong, MD
Sidney Kimmel Comprehensive Cancer Center

1:20 PM–2:00 PM

Patient and Survivor Care

Kavitha Ramchandran, MD
Stanford University

Abstract LBA2: Overall survival results of a randomized trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. (Ethan Basch)
Abstract LBA10000: Long-term results of a phase II randomized controlled trial (RCT) of a psychological intervention (Conquer Fear) to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors. (Jane Beith)
Abstract LBA10004: SCORAD III: Randomised non-inferiority phase III trial of single dose radiotherapy (RT) compared to multifraction RT in patients (pts) with metastatic spinal canal compression (SCC). (Peter Hoskin)
Abstract 10006: American Cancer Society (ACS) Nutrition and Physical Activity Guidelines after colon cancer diagnosis and disease-free (DFS), recurrence-free (RFS), and overall survival (OS) in CALGB 89803 (Alliance). (Erin Van Blarigan)
Abstract 10009: FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the US food and Drug Administration. (Harpreet Singh)

2:00 PM–2:10 PM

Question and Answer: Patient and Survivor Care

Kavitha Ramchandran, MD
Stanford University

2:10 PM–2:30 PM

Break

2:30 PM–3:10 PM

Head and Neck Cancer

Alain P. Algazi, MD
University of California, San Francisco

Abstract 6000: Phase III randomized trial of chemotherapy with or without bevacizumab (B) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Survival analysis of E1305, an ECOG-ACRIN Cancer Research Group trial. (Athanassios Argiris)
Abstract 6002: A multicenter randomized controlled trial (RCT) of adjuvant chemotherapy (CT) in nasopharyngeal carcinoma (NPC) with residual plasma EBV DNA (EBV DNA) following primary radiotherapy (RT) or chemoradiation (CRT). (Anthony Chan)
Abstract 6007: Phase III randomized trial comparing weekly versus three-weekly (W3W) cisplatin in patients receiving chemoradiation for locally advanced head and neck cancer. (Vanita Noronha)
Abstract 6009: Genomic determinants of response to pembrolizumab in head and neck squamous cell carcinoma (HNSCC). (Robert Haddad)

3:10 PM–3:50 PM

Lung Cancer—Non-small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Joel Neal, MD, PhD
Stanford Cancer Institute

Abstract 8500: Gefitinib (G) versus vinorelbine+cisplatin (VP) as adjuvant treatment in stage II-IIIA (N1-N2) non-small-cell lung cancer (NSCLC) with EGFR-activating mutation (ADJUVANT): A randomized, Phase III trial (CTONG 1104). (Yi-Long Wu)
Abstract 8503: Nivolumab (nivo) ± ipilimumab (ipi) in advanced small-cell lung cancer (SCLC): First report of a randomized expansion cohort from CheckMate 032. (Matthew Hellmann)
Abstract 8505: Randomized trial of cisplatin and etoposide in combination with veliparib or placebo for extensive stage small cell lung cancer: ECOG-ACRIN 2511 study. (Taofeek Owonikoko)
Abstract LBA8507: Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial. (Arnaud Scherpereel)

3:50 PM–4:30 PM

Lung Cancer—Non-small Cell Metastatic

Jonathan Riess, MD, MS
University of California, Davis

Abstract 9000: Progression after the next line of therapy (PFS2) and updated OS among patients (pts) with advanced NSCLC and PD-L1 tumor proportion score (TPS) 50% enrolled in KEYNOTE-024. (Julie Brahmer)
Abstract 9004: Efficacy and safety results from AvaALL: An open-label, randomized phase III trial of standard of care (SOC) with or without continuous bevacizumab (Bev) treatment beyond progression (PD) in patients (pts) with advanced non-small cell lung cancer (NSCLC) progressing after first-line Bev and chemotherapy (chemo). (Jaafar Bennouna)
Abstract LBA9007: Dacomitinib versus gefitinib for the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer (ARCHER 1050): A randomized, open-label phase III trial. (Tony Mok)
Abstract LBA9008: Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. (Alice Shaw)

4:30 PM–4:50 PM

Panel Question and Answer: Head and Neck Cancer and Lung Cancers

Alain P. Algazi, MD
University of California, San Francisco

Joel Neal, MD, PhD
Stanford Cancer Institute

Jonathan Riess, MD, MS
University of California, Davis